title: Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol.
abstract: Tocotrienols are one of the most potent anticancer agents of all natural compounds and the anticancer property may be related to the inactivation of Ras family molecules. The anticancer potential of tocotrienols, however, is weakened due to its short elimination half life in vivo. To overcome the disadvantage and reinforce the anticancer activity in tocotrienols, we synthesized a redox-silent analogue of alpha-tocotrienol (T3), 6-O-carboxypropyl-alpha-tocotrienol (T3E). We estimated the possibility of T3E as a new anticancer agent against lung adenocarcinoma showing poor prognosis based on the mutation of ras gene. T3E showed cytotoxicity against A549 cells, a human lung adenocarcinoma cell line with a ras gene mutation, in a dose-dependent manner (0-40 microM), whereas T3 and a redox-silent analogue of alpha-tocopherol (T), 6-O-carboxypropyl-alpha-tocopherol (TE), showed much less cytotoxicity in cells within 40 microM. T3E cytotoxicity was based on the accumulation of cells in the G1-phase of the cell-cycle and the subsequent induction of apoptosis. Similar to this event, 24-hr treatment of A549 cells with 40 microM T3E caused the inhibition of Ras farnesylation, and a marked decrease in the levels of cyclin D required for G1/S progression in the cell-cycle and Bcl-xL, a key anti-apoptotic molecule. Moreover, the T3E-dependent inhibition of RhoA geranyl-geranylation is an inducing factor for the occurrence of apoptosis in A549 cells. Our results suggest that T3E suppresses Ras and RhoA prenylation, leading to negative growth control against A549 cells. In conclusion, a redox-silent analogue of T3, T3E may be a new candidate as an anticancer agent against lung adenocarcinoma showing poor prognosis based on the mutation of ras genes.
authors.affiliation: Department of Biochemistry, Osaka City University Medical School, Osaka, Japan. yano@nih.go.jp
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Yano
authors.forename: Haruna
authors.initials: H
authors.lastname: Satoh
authors.forename: Keiko
authors.initials: K
authors.lastname: Fukumoto
authors.forename: Itsumaro
authors.initials: I
authors.lastname: Kumadaki
authors.forename: Tomio
authors.initials: T
authors.lastname: Ichikawa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yamada
authors.forename: Kiyokazu
authors.initials: K
authors.lastname: Hagiwara
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Yano
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000975:Antioxidants / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D016923:Cell Death; D056741:Cyclin D; D016213:Cyclins / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D010084:Oxidation-Reduction; D011379:Prognosis; D024508:Tocotrienols / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D018631:ras Proteins / Q000378:metabolism
chemical_list: C501588:6-O-carboxypropyl-alpha-tocotrienol; D000975:Antioxidants; D056741:Cyclin D; D016213:Cyclins; D024508:Tocotrienols; D018631:ras Proteins